Voyager Therapeutics (FRA:VT6) Cyclically Adjusted FCF per Share: €-0.94 (As of Mar. 2026)


FRA:VT6 Voyager Therapeutics Inc FRA:VT6
53 GF Score
Price €3.16
GF Value €1.40
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Voyager Therapeutics Cyclically Adjusted FCF per Share?

Voyager Therapeutics FRA:VT6 +5.20% 53 Cyclically Adjusted FCF per Share is €-0.94 as of Mar. 2026. GuruFocus rates FRA:VT6 with a GF Score™ of 53/100 and a GF Value™ of €1.40 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Voyager Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.486. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.94 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-06), Voyager Therapeutics's current stock price is €3.158. Voyager Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-0.94. Voyager Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Voyager Therapeutics  (FRA:VT6) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Voyager Therapeutics Cyclically Adjusted FCF per Share Related Terms


Voyager Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Voyager Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyager Therapeutics Cyclically Adjusted FCF per Share Chart

Voyager Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.41 -0.91

Voyager Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.06 -0.79 -0.90 -0.91 -0.94

FRA:VT6 vs KROS, CDXS, CAMP: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Voyager Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Voyager Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Voyager Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


FRA:VT6
53GF Score
Voyager Therapeutics Inc FRA:VT6
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Voyager Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Voyager Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.486/330.2130*330.2130
=-0.486

Current CPI (Mar. 2026) = 330.2130.

Voyager Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.350 241.018 -0.480
201609 -0.375 241.428 -0.513
201612 -0.630 241.432 -0.862
201703 -0.625 243.801 -0.847
201706 -0.576 244.955 -0.776
201709 -0.523 246.819 -0.700
201712 -0.432 246.524 -0.579
201803 1.200 249.554 1.588
201806 -0.638 251.989 -0.836
201809 -0.492 252.439 -0.644
201812 -0.676 251.233 -0.889
201903 3.292 254.202 4.276
201906 -0.784 256.143 -1.011
201909 -0.562 256.759 -0.723
201912 -0.653 256.974 -0.839
202003 -0.742 258.115 -0.949
202006 -0.554 257.797 -0.710
202009 -0.674 260.280 -0.855
202012 -0.563 260.474 -0.714
202103 -0.485 264.877 -0.605
202106 -0.507 271.696 -0.616
202109 -0.481 274.310 -0.579
202112 0.254 278.802 0.301
202203 0.821 287.504 0.943
202206 -0.487 296.311 -0.543
202209 -0.421 296.808 -0.468
202212 -0.323 296.797 -0.359
202303 2.726 301.836 2.982
202306 -0.043 305.109 -0.047
202309 -0.466 307.789 -0.500
202312 -0.446 306.746 -0.480
202403 0.912 312.332 0.964
202406 -0.524 314.175 -0.551
202409 -0.440 315.301 -0.461
202412 -0.242 315.605 -0.253
202503 -0.611 319.799 -0.631
202506 -0.508 322.561 -0.520
202509 -0.453 324.800 -0.461
202512 -0.448 324.054 -0.457
202603 -0.486 330.213 -0.486

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.94 mean?
Voyager Therapeutics (FRA:VT6) has a Cyclically Adjusted FCF per Share of €-0.94 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Voyager Therapeutics and its competitors.
Is Voyager Therapeutics' Cyclically Adjusted FCF per Share too high?
Voyager Therapeutics' current Cyclically Adjusted FCF per Share is €-0.94. Overall, Voyager Therapeutics has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' Cyclically Adjusted FCF per Share compare to KROS and CDXS?
Voyager Therapeutics' Cyclically Adjusted FCF per Share of €-0.94 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Voyager Therapeutics and its competitors. Voyager Therapeutics's current Cyclically Adjusted FCF per Share is €-0.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Voyager Therapeutics (FRA:VT6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.40, compared to a current price of €3.16 — trading 125.6% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.94. Voyager Therapeutics' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Voyager Therapeutics (FRA:VT6), the current Cyclically Adjusted FCF per Share is €-0.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Voyager Therapeutics (FRA:VT6) Overvalued in 2026?

Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued. The current stock price of €3.16 is trading 125.6% above its estimated GF Value™ of €1.40. GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:VT6:

  • Cyclically Adjusted FCF per Share: €-0.94
  • GF Value™: €1.40 vs. price of €3.16 (125.6% above fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the FRA:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Voyager Therapeutics Business Description

Other Exchanges VYGR:USAVYGR:Mexico
Address 75 Hayden Avenue, Lexington, MA, USA, 02421
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
53GF Score

Get the complete analysis for FRA:VT6

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.16
Price
€1.40
GF Value